Product NDC: | 0069-0152 |
Proprietary Name: | Cytarabine |
Non Proprietary Name: | Cytarabine |
Active Ingredient(s): | 100 mg/5mL & nbsp; Cytarabine |
Administration Route(s): | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
Dosage Form(s): | INJECTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0069-0152 |
Labeler Name: | Pfizer Laboratories Div Pfizer Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA200915 |
Marketing Category: | ANDA |
Start Marketing Date: | 20111214 |
Package NDC: | 0069-0152-02 |
Package Description: | 10 VIAL in 1 CARTON (0069-0152-02) > 5 mL in 1 VIAL (0069-0152-01) |
NDC Code | 0069-0152-02 |
Proprietary Name | Cytarabine |
Package Description | 10 VIAL in 1 CARTON (0069-0152-02) > 5 mL in 1 VIAL (0069-0152-01) |
Product NDC | 0069-0152 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Cytarabine |
Dosage Form Name | INJECTION |
Route Name | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
Start Marketing Date | 20111214 |
Marketing Category Name | ANDA |
Labeler Name | Pfizer Laboratories Div Pfizer Inc. |
Substance Name | CYTARABINE |
Strength Number | 100 |
Strength Unit | mg/5mL |
Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |